DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

Novartis (NYSE: NVS)

102.73 -1.52 (-1.46%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NVS $102.73 -1.46%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $104.09
Previous Close $104.25
Daily Range $102.26 - $104.56
52-Week Range $84.17 - $105.82
Market Cap $246.4B
P/E Ratio 28.18
Dividend (Yield) $2.67 (2.2%)
Ex-Dividend Date
Dividend Pay Date
03/02/15
04/20/15
Volume 2,149,108
Average Daily Volume 1,136,302
Current FY EPS $5.19

Sector

Healthcare

Industry

Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website: http://www.novartis.com/

News & Commentary

3 Stocks That Could Double Your Money

Biotech has produced numerous stocks recently that have doubled or tripled in short periods of time. Here is a look at three small-cap companies with the potential to continue this trend.

Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for June 01, 2015

Is This Pfizer's Next Move?

Analysts at Deutsche Bank recently suggested that Pfizer may have interest in buying GlaxoSmithKline. While the two companies have several shared areas of interest, this megamerger is far from a perfect fit. Here's why.

Juno Therapeutics, Editas Ink Cancer Immunotherapy Deal - Analyst Blog

Stocks To Buy For 10 Years: Facebook Inc, Amazon.com, Inc, and Google Inc.

Patient tech investors should buy and hold Facebook, Amazon, and Google for at least the next ten years.

Billionaire George Soros Just Sold These 3 Stocks: Should You?

The Soros Fund Management sold Kite Pharma, Valeant Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. in the first quarter. Should you follow in its footsteps?

Will Competition Cause Teva Pharmaceutical Industries ltd. To Tumble?

The FDA has approved Novartis' biosimilar to Teva Pharmaceuticals' Copaxone.

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog

Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237

Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 21, 2015

See More NVS News...

NVS's Top Competitors

NVS $102.73 (-1.46%)
Current stock: NVS
GSK $44.37 (-0.94%)
Current stock: GSK
JNJ $100.14 (-1.00%)
Current stock: JNJ
PFE $34.75 (0.90%)
Current stock: PFE